Your session is about to expire
← Back to Search
BAX 888 for Hemophilia A
Study Summary
This trial is testing a new medication for hemophilia A to see if there are any side effects and to find the right dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 303 Patients • NCT01064284Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Is this a previously unexplored research endeavor?
"Grifols Biologicals, LLC has sponsored a total of 4 BAX 888 trials since 2007. Across 19 nations and 41 cities, these studies have concluded Phase 4 drug approval with 15 participants each on average. In the 13 years that followed, 26 more clinical studies were carried out to their completion."
Is this research in search of participants?
"Unfortunately, this medical investigation is not presently accepting individuals. Initially posted on March 31st 2018 and revised November 23rd 2021, it has since been suspended from recruitment. If you are seeking other trials, 89 clinical studies for hemophilia A and 4 for BAX 888 currently remain open to new participants."
What is the current size of the cohort enrolled in this experiment?
"Recruitment for this trial has concluded. It was initially posted on March 31st 2018 and last modified on November 23rd 2021. There are currently 89 clinical trials in search of participants with hemophilia a, as well as 4 studies recruiting patients to test BAX 888."
Is eligibility for the trial open to individuals aged 45 and above?
"This trial is open to individuals between 18 and 75 years old."
Do I meet the qualifications to partake in this medical experiment?
"In order to be accepted into this trial, participants must have been diagnosed with hemophilia A and within the age range of 18-75 years old. At present, 12 volunteers are being sought after for the research."
What therapeutic effects does BAX 888 typically bring about?
"BAX 888 is a commonly used medication for treating bleeding. It can be equally effective in managing von willebrand disease, motor neuron disorder, and desmopressin-related issues."
Are there other investigations that have explored the efficacy of BAX 888?
"Currently, there are 4 ongoing BAX 888 studies. Of these trials, two have reached the third phase of clinical testing. The majority of investigations for this treatment is located in Paris, Maryland; however, research has extended to 84 other sites worldwide."
Are there numerous health care centers in North America who are active participants in this medical study?
"The University of Colorado Hemophilia & Thrombosis Center in Aurora, California is the primary site for this medical trial. Additionally, Orthopaedic Hemophilia Treatment Centre located in Los Angeles and Gulf States Hemophilia and Thrombology Centre situated Houston are involved with 6 other participating centres nationwide."
Share this study with friends
Copy Link
Messenger